CN109069469A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN109069469A
CN109069469A CN201780012242.4A CN201780012242A CN109069469A CN 109069469 A CN109069469 A CN 109069469A CN 201780012242 A CN201780012242 A CN 201780012242A CN 109069469 A CN109069469 A CN 109069469A
Authority
CN
China
Prior art keywords
cancer
compound
formula
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780012242.4A
Other languages
English (en)
Chinese (zh)
Inventor
李嘉强
L·博罗戴恩斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of CN109069469A publication Critical patent/CN109069469A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780012242.4A 2016-01-20 2017-01-19 治疗癌症的方法 Pending CN109069469A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281004P 2016-01-20 2016-01-20
US62/281,004 2016-01-20
PCT/US2017/014163 WO2017132049A1 (en) 2016-01-20 2017-01-19 Methods for treating cancer

Publications (1)

Publication Number Publication Date
CN109069469A true CN109069469A (zh) 2018-12-21

Family

ID=58737850

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780012242.4A Pending CN109069469A (zh) 2016-01-20 2017-01-19 治疗癌症的方法

Country Status (7)

Country Link
US (2) US20190076392A1 (enExample)
EP (1) EP3405189A1 (enExample)
JP (1) JP2019506392A (enExample)
CN (1) CN109069469A (enExample)
CA (1) CA3011800A1 (enExample)
TW (1) TW201731500A (enExample)
WO (1) WO2017132049A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164438A (zh) * 2018-10-12 2021-07-23 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736564A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
AU2016247319A1 (en) * 2015-04-17 2017-11-02 Boston Biomedical, Inc. Methods for treating cancer
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
WO2025040686A1 (en) * 2023-08-21 2025-02-27 Abliva Ab Quinones for use in the treatment of red blood cell enzymopathies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036101A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
WO2014169078A2 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101908208B1 (ko) 2010-03-19 2018-10-15 보스톤 바이오메디칼, 인크. 암 줄기 세포를 표적화하는 신규 화합물 및 조성물
JP2013522326A (ja) 2010-03-19 2013-06-13 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の方法
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
AU2016247319A1 (en) * 2015-04-17 2017-11-02 Boston Biomedical, Inc. Methods for treating cancer
US20180140572A1 (en) * 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036101A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
WO2014169078A2 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
赵志刚等: "《药品超说明书使用循证评价2015年版》", 31 May 2015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164438A (zh) * 2018-10-12 2021-07-23 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案

Also Published As

Publication number Publication date
TW201731500A (zh) 2017-09-16
EP3405189A1 (en) 2018-11-28
CA3011800A1 (en) 2017-08-03
US20190224157A1 (en) 2019-07-25
US20190076392A1 (en) 2019-03-14
JP2019506392A (ja) 2019-03-07
WO2017132049A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
CN109069469A (zh) 治疗癌症的方法
US20180085341A1 (en) Methods for treating cancer
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20190231735A1 (en) Methods for treating cancer
US10646464B2 (en) Methods for treating cancer
JP2019519573A (ja) がんを処置するための方法
TWI733026B (zh) 昭和草萃取物於治療乳癌之用途
TW201709905A (zh) 治療癌症之方法
JP2024123152A (ja) 化学療法難治性がんの治療のための新しい併用薬方法
Lee et al. In vivo activity of ARRY-380, a potent, small molecule inhibitor of ErbB2 in combination with trastuzumab, docetaxel or bevacizumab
WO2020199973A1 (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
KR102236686B1 (ko) 2-(3-[2-(1-시클로헥센-1-일)에틸]-6,7-디메톡시-4-옥소-3,4-디히드로-2-퀴나졸리닐술파닐)-n-(4-에틸페닐)부탄아미드를 유효성분으로 포함하는 암 치료 또는 예방용 조성물
Jayaraman et al. Nanoemulsions-Based Systems for Breast
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221